Hims & Hers Charts Ambitious Course with Dual Acquisitions

Following a year of stock market volatility, telehealth provider Hims & Hers Health is aggressively pursuing its long-term 2030 vision. The company recently unveiled two strategic acquisitions designed to fuel expansion on both geographic and technological fronts, even as its share price undergoes a correction.

Operational Strength and Strategic Moves

These strategic initiatives are built upon a foundation of robust operational performance. For the third quarter of 2025, the company reported a 49% surge in revenue, reaching nearly $600 million. Adjusted EBITDA also saw significant growth, climbing to over $78 million.

Against this backdrop of strong fundamentals, management has set its sights on two key deals. The first is a geographic push into the Canadian healthcare market through the acquisition of Livewell, a digital platform specializing in weight-loss treatments. This cash-funded transaction aligns with the global growth in obesity treatments and aims to make healthcare more accessible for Canadians.

Concurrently, Hims & Hers is bolstering its technological capabilities with a planned takeover of YourBio Health. Based in Boston, YourBio has pioneered a painless capillary blood collection method using microneedles. This technology is slated for integration into the company’s recently launched “Labs” service, facilitating at-home health testing for customers. The deal is anticipated to close in early 2026.

Should investors sell immediately? Or is it worth buying Hims & Hers?

Share Performance and Future Catalysts

Despite the compelling growth narrative, the stock has faced recent technical pressure. While shares are up approximately 37% year-to-date, a notable correction has occurred. Closing at €33.78 on Friday, the stock trades almost 49% below its 52-week high of over €66.

Analyst sentiment reflects this uncertainty, with price targets ranging widely from $32 to $68. A potential future catalyst lies in ongoing discussions with pharmaceutical giant Novo Nordisk. Hims & Hers is exploring the possibility of offering popular weight-loss medications like Wegovy directly on its platform, though no final agreement has been reached.

Integrating Acquisitions and Returning Capital

Looking ahead, the company’s focus will be on the rapid integration of its new acquisitions. Management has also taken steps to reinforce investor confidence by authorizing a $250 million share repurchase program.

For the current fourth quarter, revenue is projected to land between $605 million and $625 million. The next significant milestone will be the quarterly report in early 2026, which will provide critical insight into whether the company’s ambitious growth targets remain on track.